Brisbane Economic Development Agency’s Post

🚨 Big News in Medical Tech 🚨 Route 92 Medical, a neurovascular interventional solutions company based in San Mateo, just raised $50M in Series F extension funding! 💰 Led by Novo Holdings, the round also included US Venture Partners, Norwest Venture Partners, InnovaHealth Partners, LP, and The Vertical Group. 🏦 In connection with the investment, Noel Jee, Partner, Growth Investments, Novo Holdings US, joins the Route 92 Board of Directors. 🎯 What’s Next? The funding will accelerate global commercialization of their neurovascular intervention portfolio and support regulatory approvals in new regions. 🌍 Why it Matters: With innovations like the FreeClimb, HiPoint Catheter Systems, and the Monopoint® Operating Platform—powered by the Tenzing® Delivery Catheter—Route 92 is simplifying stroke treatment by streamlining procedures, reducing time and cost, and improving outcomes. ⏱️💡 CEO Tony Chou emphasizes how this investment will help Route 92 continue collaborating with neurovascular clinicians to solve real-world challenges and deliver differentiated solutions for better patient care. 🏥 Noel Jee, Partner at Novo Holdings, joins the Board of Directors to further drive this mission forward. 📈 💼 Transforming neuro intervention, one innovation at a time! 📢 Stay tuned to Future Techly for the latest updates on this groundbreaking initiative and the latest in tech and business! 💥 Source: FinSMEs #MedicalTech #Neurovascular #Funding #Innovation #Healthcare #Route92 #PatientCare #FutureTechly

Looking at the future of cardiac care, how can major device companies collaborate with the startup ecosystem? In this clip Chris Eso, Vice President, Global Head of Corporate and Business Development, M&A and Ventures at Medtronic, predicts that in the next 10-20 years, medical devices will be highly interconnected and data-driven. This shift marks a significant shift from traditional Medtech. Achieving this level of connectivity will require extensive collaboration between major device companies and the startup ecosystem. The full panel shares insights on fostering successful partnerships, enhancing patient care, and driving the next wave of breakthroughs in cardiac treatment and management. Tune into the full panel “Accelerating Cardiac Care Innovation: How Can Major Device Companies Collaborate with the Startup Ecosystem?” to hear more from Ken Nelson, Nate Harrington, Lisa Suennen, GCB.D, Chris Eso, and David Hochman.

I love seeing these clips from LSI USA 2024. That conference went by so quickly that I missed too many terrific panels! I appreciate Chris Eso's take in this clip: “If you think about what the world looks like in 10-15-20 years from now from a medical device, it’s going to be all connected. It’s going to be all data generating. It’s going to be how you use that data to get better outcomes longer term.” This is exactly why The Shape Sensing Company is building tools to track surgical devices. Not just for navigation during procedures (which is a huge benefit), but the data associated with the navigation will inform us on what went right, what went wrong, and how to improve patient outcomes in the future. Fiber optic 3D guidance is the only technology that can provide full-length, three-dimensional device location, bending, and torque tracking for any tool used in a procedure. And we're not too far off from the future that Chris talks about being a reality. #patientoutcomes #digitalsurgery #futureofhealthcare #fiberoptics

🚀 Atlantic Bridge’s portfolio company LaNua Medical, an innovative Irish MedTech start-up and University College Dublin spin-out, has secured €6 million in seed funding! 🎉 This funding will accelerate the development of LaNua’s groundbreaking ECORE™ device, designed to modernise embolisation procedures. With the potential to enhance patient outcomes, LaNua’s platform technology represents a major leap forward in treating internal bleeding, vascular malformations, and tumors. The company will be hiring across R&D and Quality roles as it builds towards international expansion, targeting the US market in 2025. 👏Congratulations to Dr. Cormac Farrelly, Tom Fitzmaurice, Dr. Eoin O’Cearbhaill, and Dr. Sajjad Amiri on this milestone! Learn more about their work here: https://lnkd.in/d75cPXXu #MedTech #Innovation #HealthTech #Ireland #Investment

We are delighted to share that Xinzeyuan, a leading platform in the minimally invasive surgical supply chain and a portfolio company of Qiming Venture Partners, has successfully completed its B+ round of financing, raising nearly RMB 100 million. Qiming Venture Partners has led in the Series B round and continued to invest in this round. The company has secured two rounds of financing within just six months, reflecting strong recognition and confidence from investment institutions. Founded in 2015, Xinzeyuan has built a robust platform centered on the full supply chain of minimally invasive medical devices. Its core business spans four key areas: rigid endoscopes, flexible endoscopes, endoscopic surgical devices, and minimally invasive surgical devices, serving a wide range of medical brands. Oscar Zhang, Partner of Qiming Venture Partners, said, "In the six months since we led Xinzeyuan's Series B round, the company has made significant strides in product development and business expansion. We have been continually impressed by Xinzeyuan's innovation and execution. We remain confident in the future of China's medical device industry and are committed to supporting exceptional companies like Xinzeyuan as they grow and make their mark on the global stage." #InnovationInHealthcare #MinimallyInvasiveSurgery #MedicalDevices #VentureCapital #MedTechLeadership #QimingPortfolio #QimingHealthcare

When asked to describe the past 20 years of NeuroNexus, Rio describes the time as "transformative". "Building a company from the ground up involves innovative thinking and a forward-looking vision," he continues. "NeuroNexus has undergone a remarkable evolution over the past 20 years. During the challenging but exciting startup phase, we faced significant uncertainty about the viability of our business. Grant funding played a crucial role in supporting our early efforts. As we grew, we expanded our team and formed successful partnerships with major players like Philips Research." "Creating intellectual property was another milestone that added significant value to our company. This positioned us well for our eventual acquisition by Greatbatch, which elevated our discipline and knowledge as we became a subsidiary of a publicly traded medical device company. The experience of spinning out with Nuvectra, a spinal cord stimulation company, provided us with invaluable exposure to the medtech industry." "Eventually, we came full circle and identified an opportunity to acquire NeuroNexus, transforming it back into a private company. Throughout these transitions, our resilience, grit, and discipline guided us, positioning NeuroNexus today as stronger than ever."

Q4 M&A Moves: MedTech is on Fire! 🔥 With acquisitions heating up, major players are positioning for 2025. Here’s a look at some bold moves: • Boston Scientific x Cortex: Bringing in advanced mapping tech for AFib treatment, setting new standards in cardiac care. • Merit Medical Systems, Inc. x Cook Medical: Expanding cardiovascular capabilities through lead management solutions. • Johnson & Johnson x V-Wave: Reinforcing its structural heart portfolio with innovative interatrial shunt tech. • Hologic, Inc. x Gynesonics, Inc.: Transforming women’s health with new, minimally invasive fibroid treatments. With more deals expected before year’s end, it’s clear: MedTech leaders are betting big on strategic growth and innovation. Which acquisition stands out to you?

More to come

The Medical Device Panel at RESI London Explore the evolving landscape of medical device investment with industry leaders! At RESI London, the Medical Device Panel will dive into: 💡 Emerging trends for 2024 💡 Navigating combination and software-enabled devices 💡 Overcoming regulatory challenges 💡 How startups can secure investment Hear from experts Matthew Frohn (Longwall Ventures), Sergio Levi (Mercia Ventures), Ron Petersen (Longbow Capital), and Christian Schenk (Apposite Capital), moderated by Andrew Merken (Polsinelli). 📅 Don’t miss this opportunity to gain valuable insights into this dynamic sector. Register now for RESI London on December 4: #MedicalDevices #MedTech #LifeScienceInnovation #StartupInvestment #RESILondon #LifeScienceNation #MedTechInvestors

🌟 Weekly Recap: A Week of Collaboration, and Celebration! 🌟 Last week was packed with exciting moments for NLC with HLTH, an exclusive networking dinner, successful ortho/spine panel and a festive venture day. Here's a look back at everything we had done: June 17-20: HLTH Europe We had an incredible time showcasing our health innovations at HLTH Europe. Throughout the week NLC pavilion was filled with inspiring discussions, valuable insights from venture CEOs, and a deep dive into cardiovascular, biotech, ortho/spine and general health tech solutions. It was a fantastic opportunity to connect with industry leaders and explore collaborative opportunities. June 18: Exclusive Networking Dinner We also hosted an exclusive dinner, bringing together decision-makers from the biotech, cardiovascular, ortho-spine, and general health industries. The evening was filled with enriching conversations, networking and great food. June 19: Ortho & Spine Expert Panel Besides growing our community and network, we have also engaged in meaningful discussion with professionals from our Ortho & Spine Expert Panel on technologies currently in our venture creation pipeline. We also invited three of our ventures to share their questions with the experts, as challenges and questions will continue to arise even after the venture is established. June 21: Venture Day  Wrapping up the week, we hosted the annual Venture Day, uniting NLC’s ventures from around the globe. We covered critical topics such as early-stage funding, clinical trials, market access, and more. The event concluded with a graduation ceremony celebrating the achievements of Mitracept , Aerion Bioscience, ChARM, and Neurolieve Biosciences Ltd. Here's to many more fruitful weeks ahead, and cheers to transforming healthcare! 🚀 #HealthcareInnovation #HLTHEurope #VentureDay #Networking #Healthtech #Medtech #Biotech #Cardiovascular #OrthoSpine #PanelDiscussion